PDL BioPharma to Present at the Cowen and Company 36th Annual Health Care Conference

Mar 02, 2016, 07:00 ET from PDL BioPharma, Inc.

INCLINE VILLAGE, Nev., March 2, 2016 /PRNewswire/ -- PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI) today announced that John P. McLaughlin, the company's president and chief executive officer, will present at the Cowen and Company 36th Annual Health Care Conference next week in Boston. The presentation will be webcast live and will occur on Wednesday, March 9, 2016 at 11:20 a.m. EST.

To access the live and subsequently archived webcast of the presentation, go to the company's website at http://www.pdl.com and go to "Presentations and Events." Please connect to the website at least 15 minutes prior to the presentation to allow for any software download that may be necessary. The archived webcast will be available for at least seven days following the presentation.

About PDL BioPharma
PDL manages a portfolio of patents and royalty assets, consisting of its Queen et al. patents, license agreements with various biotechnology and pharmaceutical companies, and royalty and other assets acquired. To acquire new income generating assets, PDL provides non-dilutive growth capital and financing solutions to late-stage public and private healthcare companies and offers immediate financial monetization of royalty streams to companies, academic institutions, and inventors. PDL has committed over $1 billion and funded approximately $937 million in these investments to date. PDL evaluates its investments based on the quality of the income generating assets and potential returns on investment. PDL is currently focused on acquiring new income generating assets, the management of its intellectual property and income generating assets, and maximizing value for its stockholders.

The Company was formerly known as Protein Design Labs, Inc. and changed its name to PDL BioPharma, Inc. in 2006. PDL was founded in 1986 and is headquartered in Incline Village, Nevada. PDL pioneered the humanization of monoclonal antibodies and, by doing so, enabled the discovery of a new generation of targeted treatments for cancer and immunologic diseases for which it receives significant royalty revenue.

PDL BioPharma and the PDL BioPharma logo are considered trademarks of PDL BioPharma, Inc.

Logo - http://photos.prnewswire.com/prnh/20110822/SF55808LOGO

 

SOURCE PDL BioPharma, Inc.



RELATED LINKS

http://www.pdl.com
http://www.pdl.com